Search
User Profile
Change
Select your user profile

The future cobas® Mass Spec solution from Roche*

*cobas® Mass Spec solution is in development. Not available for sale or distribution in the USA. At launch, cobas® Mass Spec will be in a stand-alone configuration only. All other configurations, including clinical chemistry and immunochemistry analytical units, will be available at a later date.

Fully integrating mass spec into the routine laboratory

Mass spectrometry today

Mass spectrometry is renowned for its high sensitivity, specificity and accuracy and is therefore considered the gold standard in several clinical indications.1-7

Research8 shows that many clinical laboratories would like to benefit from mass spectrometry in order to expand and enhance their test offering, but struggle to do so due to various limitations of the existing solutions on the market.

  • High technology and operational complexity
  • High manual burden, lack of integration and standardization
  • The need for highly specialized and trained expert staff

 

The future of mass spectrometry from Roche*

Using feedback from customers, Roche is developing a true technological revolution – an entirely automated clinical mass spectrometry solution for the routine lab.

 

cobas® Mass Spec* is designed to have: 

Seamless integration

Into clinical chemistry and immunochemistry testing, as well as lab automation and IT

Full automation

From sample preparation to results interoperation with random access operation

High throughput

To fit the needs of the routine laboratory for fast and predictable turnaround times – up to 100 samples/hour

Broad assay menu

Consolidated on a single platform with standardized performance traceable to reference methods, >60 analytes planned

Are you interested in mass spectrometry testing? Register now to receive the latest launch updates. 
Form Successfully Submitted!
Thank you for your submission!
text
close

References

  1. Handelsman, D. J. Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science. Hum Reprod 32, 1147-1150 (2017). TDM (4,5,8,9,12-14).
  2. De Rose, D. U. et al. Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age. Int J Mol Sci 21, (2020).
  3. Gong, Z. S. et al. A high-throughput LC-MS/MS method for the quantification of four immunosuppressant drugs in whole blood. Clin Chim Acta 498, 21-26, (2019).
  4. Hörber, S., Peter, A., Lehmann, R. & Hoene, M. Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS/MS-based clinical analyzer suggests a new era in laboratory medicine. Clin Chem Lab Med, (2020).
  5. McShane, A. J., Bunch, D. R. & Wang, S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. Clin Chim Acta 454, 1-5, (2016).
  6. Zhang, Y. & Zhang, R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal 10, 81-94, (2018).
  7. Sommerfeld-Klatta, K., Zielińska-Psuja, B., Karaźniewcz-Łada, M. & Główka, F. K. New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs). Molecules 25, (2020).
  8. Business potential of clinical Mass Spectrometry, usage of CMS in Seven target countries. Study number 40846131.